FI3558314T3 - Rho-kinaasin estäjä ba-1049 (r) ja sen aktiivisia aineenvaihduntatuotteita - Google Patents
Rho-kinaasin estäjä ba-1049 (r) ja sen aktiivisia aineenvaihduntatuotteita Download PDFInfo
- Publication number
- FI3558314T3 FI3558314T3 FIEP17882341.5T FI17882341T FI3558314T3 FI 3558314 T3 FI3558314 T3 FI 3558314T3 FI 17882341 T FI17882341 T FI 17882341T FI 3558314 T3 FI3558314 T3 FI 3558314T3
- Authority
- FI
- Finland
- Prior art keywords
- pharmaceutical formulation
- formulation according
- kinase inhibitor
- active metabolites
- treatment
- Prior art date
Links
- 239000002207 metabolite Substances 0.000 title 1
- 239000003590 rho kinase inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 2
- 201000008450 Intracranial aneurysm Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000036244 malformation Effects 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Compounds Of Unknown Constitution (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437181P | 2016-12-21 | 2016-12-21 | |
| PCT/US2017/031836 WO2018118109A1 (en) | 2016-12-21 | 2017-05-09 | Rho kinase inhibitor ba-1049 (r) and active metabolites thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3558314T3 true FI3558314T3 (fi) | 2024-11-29 |
Family
ID=62627011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP17882341.5T FI3558314T3 (fi) | 2016-12-21 | 2017-05-09 | Rho-kinaasin estäjä ba-1049 (r) ja sen aktiivisia aineenvaihduntatuotteita |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP4509138A3 (enExample) |
| JP (2) | JP7117306B2 (enExample) |
| DK (1) | DK3558314T3 (enExample) |
| ES (1) | ES3002432T3 (enExample) |
| FI (1) | FI3558314T3 (enExample) |
| PL (1) | PL3558314T3 (enExample) |
| PT (1) | PT3558314T (enExample) |
| WO (1) | WO2018118109A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10106525B2 (en) | 2015-01-26 | 2018-10-23 | BioAxone BioSciences, Inc. | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof |
| US10857157B2 (en) | 2015-01-26 | 2020-12-08 | BioAxone BioSciences, Inc. | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors |
| US11198680B2 (en) | 2016-12-21 | 2021-12-14 | BioAxone BioSciences, Inc. | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof |
| ES3002432T3 (en) * | 2016-12-21 | 2025-03-06 | Bioaxone Biosciences Inc | Rho kinase inhibitor ba-1049 (r) and active metabolites thereof |
| WO2019014322A1 (en) | 2017-07-11 | 2019-01-17 | BioAxone BioSciences, Inc. | KINASE INHIBITORS FOR THE TREATMENT OF DISEASES |
| SI3877364T1 (sl) * | 2018-11-06 | 2025-02-28 | Cervello Therapeutics, Llc | Inhibitorji rock kinaze |
| WO2021085645A1 (ja) | 2019-11-01 | 2021-05-06 | キリンホールディングス株式会社 | 多成分試料における物質の構造決定方法 |
| JP7213839B2 (ja) * | 2019-11-21 | 2023-01-27 | キリンホールディングス株式会社 | 結晶スポンジ法による構造解析のための結晶構造解析用試料の調製方法 |
| EP4063839A4 (en) * | 2019-11-21 | 2023-11-22 | Kirin Holdings Kabushiki Kaisha | METHOD FOR PREPARING A CRYSTAL STRUCTURAL ANALYSIS SAMPLE FOR STRUCTURAL ANALYSIS BY CRYSTAL SPONGE METHOD |
| CN115975940B (zh) * | 2021-10-15 | 2025-09-02 | 合肥中科普瑞昇生物医药科技有限公司 | 胃癌原代细胞的培养基和培养方法 |
| JPWO2023085369A1 (enExample) | 2021-11-11 | 2023-05-19 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050014783A1 (en) * | 2003-05-29 | 2005-01-20 | Schering Aktiengesellschaft | Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy |
| JP2007523202A (ja) | 2004-02-24 | 2007-08-16 | ビオアクソン・テラプティーク・インコーポレーテッド | ４置換ピペリジン誘導体 |
| JP4652112B2 (ja) | 2005-04-26 | 2011-03-16 | 富士フイルム株式会社 | 投射型表示装置 |
| JP5313125B2 (ja) | 2007-02-28 | 2013-10-09 | 旭化成ファーマ株式会社 | スルホンアミド誘導体 |
| JP2011530518A (ja) | 2008-08-05 | 2011-12-22 | アボット・ラボラトリーズ | タンパク質キナーゼの阻害剤として有用な化合物 |
| US8957093B2 (en) | 2011-06-06 | 2015-02-17 | The Scripps Research Institute | N-biphenylmethylindole modulators of PPARG |
| JP6397831B2 (ja) * | 2013-03-06 | 2018-09-26 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ阻害剤の製造方法及びその中間体 |
| ES2774923T3 (es) * | 2014-04-28 | 2020-07-23 | China Resources Pharmaceutical Holdings Company Ltd | Derivados de isoquinolinsulfonilo como inhibidores de RHO quinasa |
| US9902702B2 (en) * | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
| US9687483B2 (en) | 2015-01-26 | 2017-06-27 | BioAxone BioSciences, Inc. | Treatment of cerebral cavernous malformations and cerebral aneurysms with Rho kinase inhibitors |
| ES3002432T3 (en) * | 2016-12-21 | 2025-03-06 | Bioaxone Biosciences Inc | Rho kinase inhibitor ba-1049 (r) and active metabolites thereof |
-
2017
- 2017-05-09 ES ES17882341T patent/ES3002432T3/es active Active
- 2017-05-09 WO PCT/US2017/031836 patent/WO2018118109A1/en not_active Ceased
- 2017-05-09 DK DK17882341.5T patent/DK3558314T3/da active
- 2017-05-09 EP EP24208222.0A patent/EP4509138A3/en active Pending
- 2017-05-09 PL PL17882341.5T patent/PL3558314T3/pl unknown
- 2017-05-09 JP JP2019534685A patent/JP7117306B2/ja active Active
- 2017-05-09 FI FIEP17882341.5T patent/FI3558314T3/fi active
- 2017-05-09 EP EP17882341.5A patent/EP3558314B1/en active Active
- 2017-05-09 PT PT178823415T patent/PT3558314T/pt unknown
-
2022
- 2022-06-30 JP JP2022105969A patent/JP7461414B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3558314A1 (en) | 2019-10-30 |
| PT3558314T (pt) | 2024-12-19 |
| PL3558314T3 (pl) | 2025-02-24 |
| JP2022141695A (ja) | 2022-09-29 |
| JP7461414B2 (ja) | 2024-04-03 |
| WO2018118109A1 (en) | 2018-06-28 |
| DK3558314T3 (da) | 2024-11-04 |
| EP3558314B1 (en) | 2024-10-23 |
| JP2020502248A (ja) | 2020-01-23 |
| ES3002432T3 (en) | 2025-03-06 |
| JP7117306B2 (ja) | 2022-08-12 |
| EP4509138A3 (en) | 2025-04-23 |
| EP3558314A4 (en) | 2020-08-26 |
| EP4509138A2 (en) | 2025-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3558314T3 (fi) | Rho-kinaasin estäjä ba-1049 (r) ja sen aktiivisia aineenvaihduntatuotteita | |
| EP4501932A3 (en) | Kras g12c inhibitors | |
| FI3256218T3 (fi) | Kdm1a-estäjät sairauksien hoidossa | |
| JP2020502248A5 (enExample) | ||
| MX2015010971A (es) | Derivado novedoso de pirazol. | |
| JP2017506627A5 (enExample) | ||
| WO2017035353A8 (en) | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | |
| EP2964194A4 (en) | HEAT-SENSIBLE HYDROGEL WITH POLYMER PARTICLES FOR NON-INVENTIONAL OXULAR MEDICINAL RELEASE | |
| DK2840080T3 (da) | Nitrogenholdig heterocyklisk forbindelse eller salt deraf | |
| WO2014120808A8 (en) | Pyridone amides as modulators of sodium channels | |
| EP3412668A3 (en) | A selective inhibitor of phosphatidylinositol 3-kinase-gamma | |
| WO2016172496A8 (en) | Lsd1 inhibitors and uses thereof | |
| EP3466447A4 (en) | TOPICAL PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SHAPES OF SKIN Wounds and MANUFACTURING METHODS THEREFOR | |
| EA202091028A1 (ru) | Ароматические сульфонамидные производные для лечения ишемического инсульта | |
| EP4477222A3 (en) | Crystalline 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1h-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide hydrochloride salt | |
| WO2016112875A3 (zh) | 二联苯衍生物及其应用 | |
| WO2019040105A3 (en) | COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES | |
| WO2017034242A3 (ko) | 신규한 카테콜 유도체 및 이를 포함하는 약학적 조성물 | |
| MA46329A (fr) | Systèmes de rétraction chirurgicale comprenant des rétracteurs sternaux et des inserts hémostatiques | |
| WO2016092560A3 (en) | Dual release bilayer tablets comprising metformin | |
| LT3655395T (lt) | N-((1r,2s,sr)-5-(tret-butilamino)-2-((s)-3-(7-tret-butilpirazolo[1,5-a][1,3,5]triazin-4-ilamino)-2-oksopirolidin-1-il)cikloheksil)acetamido gamybos būdas | |
| WO2015029070A8 (en) | Co-abpbi membranes and process for the preparation thereof | |
| ES2525079A1 (es) | Actividad antiparasitaria de escuaramidas | |
| HK1221225A1 (zh) | 3，5-二氨基吡唑激酶抑制劑的藥學上可接受的鹽 | |
| EP4289420A3 (en) | Crystalline modifications of n-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine hydrochloride and n-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine salts |